Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with PMF, PPV-MF or PET-MF as confirmed by bone marrow biopsy~* Discontinuation of all drugs used to treat underlying MF disease at least 14 days prior to baseline visit~* INR \<= 1.5 or PTT value \< 1.5 x upper limit of normal (ULN) at study entry~* Hemoglobin level at least 6.5 g/dL at Screening visit~* Willingness to be transfused to treat low hemoglobin levels~Exclusion Criteria:~* Females who are pregnant, unable to comply with birth control use to avoid becoming pregnant or breastfeeding~* Males who cannot comply with birth control use to avoid fathering a child~* Platelet count \< 50 x10\^9/L or absolute neutrophil count (ANC) \< 1 x10\^9/L at the Screening visit~* Inadequate liver or renal function; Intracranial bleeds or invasive malignancy over the previous 2 years - international normalized ratio (INR) laboratory values cannot be \> 1.5 x upper limit of normal at study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib 5 mg (Type: EXPERIMENTAL): Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).